The US Food and Drug Administration has taken additional steps to ensure mutations of the COVID-19 virus do not negatively impact the efficacy of tests.

If large diagnostics companies are consolidating at a record pace these days, smaller companies are also struggling for ways to cope with the brutalities of the current market. Some are cutting back on projects or looking to eliminate altogether their involvement in diagnostics. Others are forging relations with other small companies, something they haven't done much of in the past.

Genetic testing is progressing at a faster pace than anyone envisioned just a few years ago. The question now is not whether genetic testing will ever be a business, but whether it will evolve.